SCHEMBL4225879

SCHEMBL4225879

BrCc1cccc2ccncc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNF P01375 3/20 0.49
KDM4E B2RXH2 2/20 0.44
MAPKAPK2 P49137 1/20 0.44
CYP1A2 P05177 2/20 0.40
CYP2D6 P10635 2/20 0.40
CYP2C9 P11712 2/20 0.40
CYP2C19 P33261 2/20 0.40
LMNA P02545 1/20 0.40
CYP3A4 P08684 1/20 0.40
TRPV1 Q8NER1 1/20 0.40
MAPK9 P45984 1/20 0.37
ALDH1A1 P00352 2/20 0.37
HPGD P15428 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
HTT P42858 2/20 0.37
POLB P06746 2/20 0.37
ADORA2A P29274 1/20 0.37
RAD52 P43351 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30003293 1.00 TNF (0.49) TNFKDM4EMAPKAPK2CYP1A2CYP2D6
Bromide SCHEMBL16752289 0.98 TNF (0.47) TNFKDM4EMAPKAPK2CYP1A2CYP2D6
Bromide SCHEMBL16752287 0.96 TNF (0.46) TNFKDM4EMAPKAPK2CYP1A2CYP2D6
SCHEMBL28778067 0.85 TNF (0.46) TNFKDM4EMAPKAPK2CYP1A2CYP2D6
SCHEMBL843758 0.85 LMNA (0.53) KDM4EMAPKAPK2CYP1A2CYP2D6CYP2C9
Bromide SCHEMBL20378242 0.83 LMNA (0.52) KDM4EMAPKAPK2CYP1A2CYP2D6CYP2C9
SCHEMBL20292718 0.81 TNF (0.49) TNFKDM4EMAPKAPK2CYP1A2CYP2D6
SCHEMBL4785840 0.81 TNF (0.49) TNFKDM4EMAPKAPK2CYP1A2CYP2D6
SCHEMBL3820438 0.81 TNF (0.49) TNFKDM4EMAPKAPK2CYP1A2CYP2D6
SCHEMBL6115125 0.81 TNF (0.49) TNFKDM4EMAPKAPK2CYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115232144-B Nitrogen-containing condensed ring derivative, pharmaceutical composition, and preparation method and application thereof 长春金赛药业有限责任公司 2024-04-02 CN disclosed
CN-115232144-A Nitrogen-containing fused ring derivative, pharmaceutical composition, preparation method and application thereof 长春金赛药业有限责任公司 2022-10-25 CN disclosed
US-20090192138-A1 COMPOUNDS BAESCHLIN DANIEL KASPAR 2009-07-30 US disclosed
EP-1966215-A1 CONDENSED HETEROCYCLIC COMPOUNDS USEFUL AS DPP-IV INHIBITORS Novartis AG (CH) 2008-09-10 EP disclosed
WO-2007071738-A1 CONDENSED HETEROCYCLIC COMPOUNDS USEFUL AS DPP-IV INHIBITORS NOVARTIS AG (CH) 2007-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192138-A1 COMPOUNDS DPP4, DPP3, DPP8 TNF 3556/4885KDM4E 766/4885MAPKAPK2 3639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.